BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Astrocytoma AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Treatment
681 results:

  • 1. Exploring ncRNA-mediated regulation of egfr signalling in glioblastoma: From mechanisms to therapeutics.
    Thapa R; Afzal M; Goyal A; Gupta G; Bhat AA; Almalki WH; Kazmi I; Alzarea SI; Shahwan M; Kukreti N; Ali H; Dureja H; Kumar P; Singh TG; Kuppusamy G; Singh SK; Dua K
    Life Sci; 2024 May; 345():122613. PubMed ID: 38582393
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Quantifying intra-tumoral genetic heterogeneity of glioblastoma toward precision medicine using MRI and a data-inclusive machine learning algorithm.
    Wang L; Wang H; D'Angelo F; Curtin L; Sereduk CP; Leon G; Singleton KW; Urcuyo J; Hawkins-Daarud A; Jackson PR; Krishna C; Zimmerman RS; Patra DP; Bendok BR; Smith KA; Nakaji P; Donev K; Baxter LC; Mrugała MM; Ceccarelli M; Iavarone A; Swanson KR; Tran NL; Hu LS; Li J
    PLoS One; 2024; 19(4):e0299267. PubMed ID: 38568950
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Targeting the egfr pathway: An alternative strategy for the treatment of tuberous sclerosis complex?
    Schachenhofer J; Gruber VE; Fehrer SV; Haider C; Glatter S; Liszewska E; Höftberger R; Aronica E; Rössler K; Jaworski J; Scholl T; Feucht M
    Neuropathol Appl Neurobiol; 2024 Apr; 50(2):e12974. PubMed ID: 38562027
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Molecular and functional insight into anti-egfr nanobody: Theranostic implications for malignancies.
    Tripathy RK; Pande AH
    Life Sci; 2024 May; 345():122593. PubMed ID: 38554946
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Comprehensive mutational scanning of egfr reveals TKI sensitivities of extracellular domain mutants.
    Hayes TK; Aquilanti E; Persky NS; Yang X; Kim EE; Brenan L; Goodale AB; Alan D; Sharpe T; Shue RE; Westlake L; Golomb L; Silverman BR; Morris MD; Fisher TR; Beyene E; Li YY; Cherniack AD; Piccioni F; Hicks JK; Chi AS; Cahill DP; Dietrich J; Batchelor TT; Root DE; Johannessen CM; Meyerson M
    Nat Commun; 2024 Mar; 15(1):2742. PubMed ID: 38548752
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Integrative multi-omics characterization reveals sex differences in glioblastoma.
    Jang B; Yoon D; Lee JY; Kim J; Hong J; Koo H; Sa JK
    Biol Sex Differ; 2024 Mar; 15(1):23. PubMed ID: 38491408
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.
    Choi BD; Gerstner ER; Frigault MJ; Leick MB; Mount CW; Balaj L; Nikiforow S; Carter BS; Curry WT; Gallagher K; Maus MV
    N Engl J Med; 2024 Apr; 390(14):1290-1298. PubMed ID: 38477966
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. AGCM-22, a novel cetuximab-based egfr-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy.
    Li D; Sun X; Li Y; Shang C; Dong Y; Zhao R; Zhang H; Wang Z; Fan S; Ma C; Li X
    Bioorg Med Chem; 2024 Mar; 102():117657. PubMed ID: 38428068
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities.
    Ezzati S; Salib S; Balasubramaniam M; Aboud O
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396993
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Signaling Pathways of AXL Receptor Tyrosine Kinase Contribute to the Pathogenetic Mechanisms of Glioblastoma.
    Repici A; Ardizzone A; De Luca F; Colarossi L; Prestifilippo A; Pizzino G; Paterniti I; Esposito E; Capra AP
    Cells; 2024 Feb; 13(4):. PubMed ID: 38391974
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Exploring the therapeutic mechanisms and prognostic targets of Biochanin A in glioblastoma via integrated computational analysis and in vitro experiments.
    Ge W; Yuan G; Wang D; Dong L
    Sci Rep; 2024 Feb; 14(1):3783. PubMed ID: 38360888
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
    Keric N; Krenzlin H; Kalasauskas D; Freyschlag CF; Schnell O; Misch M; von der Brelie C; Gempt J; Krigers A; Wagner A; Lange F; Mielke D; Sommer C; Brockmann MA; Meyer B; Rohde V; Vajkoczy P; Beck J; Thomé C; Ringel F
    J Neurooncol; 2024 Mar; 167(1):133-144. PubMed ID: 38326661
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Dual blockade of egfr and PI3K signaling pathways offers a therapeutic strategy for glioblastoma.
    Guo T; Wu C; Zhang J; Yu J; Li G; Jiang H; Zhang X; Yu R; Liu X
    Cell Commun Signal; 2023 Dec; 21(1):363. PubMed ID: 38115126
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.
    Hadad S; Gupta R; Oberheim Bush NA; Taylor JW; Villanueva-Meyer JE; Young JS; Wu J; Ravindranathan A; Zhang Y; Warrier G; McCoy L; Shai A; Pekmezci M; Perry A; Bollen AW; Phillips JJ; Braunstein SE; Raleigh DR; Theodosopoulos P; Aghi MK; Chang EF; Hervey-Jumper SL; Costello JF; de Groot J; Butowski NA; Clarke JL; Chang SM; Berger MS; Molinaro AM; Solomon DA
    Acta Neuropathol; 2023 Dec; 147(1):3. PubMed ID: 38079020
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Prognostic model for assessing the human glioma cell malignancy grade based on MDM2, MELK, SOX2, CDK4, DR5 and OCT4 gene expression.
    Tyagunova EE; Drozd SF; Kalennik OV; Samoylenkova NS; Savchenko EA; Danilov GV; Pavlova GV
    Zh Vopr Neirokhir Im N N Burdenko; 2023; 87(6):43-51. PubMed ID: 38054226
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. YTHDF3 Modulates egfr/ATK/ERK/p21 Signaling Axis to Promote Cancer Progression and Osimertinib Resistance of Glioblastoma Cells.
    Lee HH; Hsieh CC; Chang CC; Liao WT; Chi HC
    Anticancer Res; 2023 Dec; 43(12):5485-5498. PubMed ID: 38030188
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. RPL22L1, a novel candidate oncogene promotes temozolomide resistance by activating STAT3 in glioblastoma.
    Chen Y; Mu Y; Guan Q; Li C; Zhang Y; Xu Y; Zhou C; Guo Y; Ma Y; Zhao M; Ji G; Liu P; Sun D; Sun H; Wu N; Jin Y
    Cell Death Dis; 2023 Nov; 14(11):757. PubMed ID: 37985768
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. egfr promotes ALKBH5 nuclear retention to attenuate N6-methyladenosine and protect against ferroptosis in glioblastoma.
    Lv D; Zhong C; Dixit D; Yang K; Wu Q; Godugu B; Prager BC; Zhao G; Wang X; Xie Q; Bao S; He C; Heiland DH; Rosenfeld MG; Rich JN
    Mol Cell; 2023 Dec; 83(23):4334-4351.e7. PubMed ID: 37979586
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Enhanced Sensitivity to ALDH1A3-Dependent Ferroptosis in TMZ-Resistant Glioblastoma Cells.
    Wu Y; Franzmeier S; Liesche-Starnecker F; Schlegel J
    Cells; 2023 Oct; 12(21):. PubMed ID: 37947601
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Unveiling Novel Avenues in mTOR-Targeted Therapeutics: Advancements in Glioblastoma treatment.
    Singh S; Barik D; Lawrie K; Mohapatra I; Prasad S; Naqvi AR; Singh A; Singh G
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834408
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 35.